FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | Sample | Privacy

Editor's Corner

Pfizer revels in massive Prevnar vax job

Pfizer ($PFE) announced in December it had extended its advance market commitment (AMC) to the Global Alliance for Vaccine and Immunisation (GAVI) for the pneumococcal vaccine Prevnar 13. The drug giant promised an additional 180 million doses through 2023, as did GlaxoSmithKline ($GSK), for its pneumococcal vaccine on top of an existing promise for 300 million doses. Total commitment: 480 million steeply discounted doses.

Report

Special Report

Fierce's 2011 warning letters report

The trend in pharma GMP warning letters for 2011 is that there are more of them, with a higher proportion of warnings to foreign plants, as the letters in this report illustrate.

Report>>